Pharmacotherapy for Obesity and Changes in Eating Behavior: a Patient and Physician ’s Perspective
This article, co-authored by a patient with obesity, diabetes, and hypertension, and an obesity medicine specialist, discusses the patient ’s experience with the onset of diabetes complicating obesity and with her frustration living with these diagnoses until finding an obesity medicine specialist physician who helped her lose weight and reverse her diabetes. The patient continues to maintain a significant weight loss and is diabetes free for 5.5 years after treatment initiation. The physician discusses the application of combination treatment that can be effective in diabetes reversal in such cases. He also dis...
Source: Advances in Therapy - July 1, 2016 Category: Drugs & Pharmacology Source Type: research

Health Self-Efficacy Among Populations with Multiple Chronic Conditions: the Value of Patient-Centered Communication
Abstract Introduction Using cross-sectional survey data, we assessed the association between chronic illness burden and health-related self-efficacy, evaluating whether patient-centered communication is associated with self-efficacy and if that relationship varies by chronic illness burden. Methods Data were from the Health Information National Trends Survey, a cross-sectional survey of the US adult population collected in 2012–2013 (n = 3630). Health-related self-efficacy was measured with the item: “Overall, how confident are you ...
Source: Advances in Therapy - June 29, 2016 Category: Drugs & Pharmacology Source Type: research

Promoting Patient and Family Partnerships in Ambulatory Care Improvement: A Narrative Review and Focus Group Findings
Conclusion This paper describes emergent mechanisms and processes that ambulatory care practices use to partner with patients and families in QI including outcomes, facilitators, and challenges. Funding Gordon and Betty Moore Foundation. (Source: Advances in Therapy)
Source: Advances in Therapy - June 28, 2016 Category: Drugs & Pharmacology Source Type: research

Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis
Conclusion Patients who switched TNFi had higher pre-treatment DAS28 and higher overall costs than patients who received the same TNFi as either single or interrupted therapy. Funding This research was funded by Immunex Corp., a fully owned subsidiary of Amgen Inc., and by VA HSR&D Grant SHP 08-172. (Source: Advances in Therapy)
Source: Advances in Therapy - June 28, 2016 Category: Drugs & Pharmacology Source Type: research

Impact of Treatment with Naloxegol for Opioid-Induced Constipation on Patients’ Health State Utility
Conclusion These analyses suggest that treatment with naloxegol improves patients’ health state utility; driven predominantly by the relief of patients’ constipation. Funding AstraZeneca. (Source: Advances in Therapy)
Source: Advances in Therapy - June 24, 2016 Category: Drugs & Pharmacology Source Type: research

Factors and Regional Differences Associated with Endometriosis: A Multi-Country, Case–Control Study
Conclusion The findings provide insight into potential risk factors for endometriosis and differences between regions in terms of endometriosis management and symptomatology. Further investigations are required to confirm the associations found in this study. Trial registration ClinicalTrials.gov identifier, NCT01351051. Funding Ipsen. (Source: Advances in Therapy)
Source: Advances in Therapy - June 24, 2016 Category: Drugs & Pharmacology Source Type: research

Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States
Conclusion In the GT1 HCV population coinfected with HIV, 3D ± R was cost-effective compared to NT, SOF + R, and SOF + PR. In the treatment-naïve sub-population, 3D ± R was cost-effective compared to NT and SOF/LDV. (Source: Advances in Therapy)
Source: Advances in Therapy - June 24, 2016 Category: Drugs & Pharmacology Source Type: research

Role of Side Effects, Physician Involvement, and Patient Perception in Non-Adherence with Oral Bisphosphonates
The objective of this study was to assess reasons for non-adherence with oral bisphosphonates among osteoporotic women. Methods A cross-sectional patient survey of women who initiated therapy with risedronate or alendronate between the years 2010 and 2012 were non-adherent [Medication Possession Ratio (MPR)
Source: Advances in Therapy - June 21, 2016 Category: Drugs & Pharmacology Source Type: research

Ovulation Induction is a More Effective Stimulant on Antiovarian Antibody Production than In Vitro Fertilization
Conclusion AOA levels of IVF patients were found to be higher than the fertile control groups’. AOA was found to be related to infertility in patients who had a longer duration of infertility and repeated ovulation induction procedures without IVF. COH and OPU during an IVF cycle did not cause an increase in AOA levels. (Source: Advances in Therapy)
Source: Advances in Therapy - June 21, 2016 Category: Drugs & Pharmacology Source Type: research

Healthcare Costs and Resource Utilization in Patients with Infantile Spasms Treated with H.P. Acthar Gel ®
Conclusion Patients prescribed Acthar within 30 days of their IS diagnoses tended to have fewer outpatient services performed compared to patients prescribed Acthar later in the disease process. Although additional research is needed to confirm these exploratory findings, physicians may consider early treatment with Acthar to manage IS. Funding This study was funded by a grant to the University of Washington from Mallinckrodt Pharmaceuticals. (Source: Advances in Therapy)
Source: Advances in Therapy - June 20, 2016 Category: Drugs & Pharmacology Source Type: research

Healthcare Costs and Resource Utilization in Patients with Multiple Sclerosis Relapses Treated with H.P. Acthar Gel ®
This study evaluated utilization and costs for the management of MS relapses with H.P. Acthar® Gel (repository corticotropin injection; Acthar; Mallinckrodt) compared to receipt of plasmapheresis (PMP) or intravenous immunoglobulin (IVIG) among patients with MS who experienced multiple relapses. Methods We identified patients with MS diagnoses who had relapses treated with intravenous methylprednisolone (IVMP), the first-line treatment for MS relapse. Patients who were treated for the subsequent relapses were eligible for the study. We analyzed 12- and 24-month healthcare utiliza...
Source: Advances in Therapy - June 17, 2016 Category: Drugs & Pharmacology Source Type: research

Comprehensive Study of Patients’ Compliance with Sublingual Immunotherapy in House Dust Mite Perennial Allergic Rhinitis
Conclusion Our results showed that two out of three patients with house dust mite-induced allergic rhinitis adhered to the SLIT treatment. Multidisciplinary and integral solutions are needed to improve the compliance, with special attention paid to adolescents. Funding Stallergenes Greer Spain. (Source: Advances in Therapy)
Source: Advances in Therapy - June 16, 2016 Category: Drugs & Pharmacology Source Type: research

Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline Characteristics
Abstract Introduction To investigate the efficacy of a treatment strategy with latanoprost and dorzolamide in primary pediatric glaucoma patients partially responsive to surgery. Methods Single arm, prospective, interventional multicenter study. Primary pediatric glaucoma patients younger than 13 years after a single surgical procedure with IOP between 22 and 26 mmHg were considered eligible. At baseline, patients were allocated to latanoprost monotherapy once daily. Depending on intraocular pressure (IOP) reduction at first visit, the patients...
Source: Advances in Therapy - June 16, 2016 Category: Drugs & Pharmacology Source Type: research

The Role of Intravoxel Incoherent Motion MRI in Predicting Early Treatment Response to Chemoradiation for Metastatic Lymph Nodes in Nasopharyngeal Carcinoma
Conclusions The present study indicated that the initial f value may be more accurate than the initial D*, D, and ADC in the early prediction of treatment response to chemoradiotherapy for metastatic lymph nodes in patients with NPC. (Source: Advances in Therapy)
Source: Advances in Therapy - June 13, 2016 Category: Drugs & Pharmacology Source Type: research

Management of Pemphigus Vulgaris
Conclusion The review findings emphasize the importance of early diagnosis, early initiation of treatment, and use of steroid-sparing adjuvants to allow a reduced total dose and duration on corticosteroids. Also highlighted is the need for more RCTs. (Source: Advances in Therapy)
Source: Advances in Therapy - June 10, 2016 Category: Drugs & Pharmacology Source Type: research

Do Corticosteroids Still Have a Role in the Management of Third Molar Surgery?
Conclusion Although there are some conflicting effects, the results of this analysis shows in general the benefits derived from short-term use of corticosteroids in relation to pain, swelling and trismus following third molar surgical extraction, with no side effects observed. Funding This work was supported by the University of Malaya’s High Impact Research grant UM.C/625/1/HIR/MOHE/05. (Source: Advances in Therapy)
Source: Advances in Therapy - June 10, 2016 Category: Drugs & Pharmacology Source Type: research

Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438)
Abstract Proton pump inhibitors (PPIs) are widely prescribed as first-line therapy for the treatment of acid-related diseases, such as peptic ulcers and gastro-esophageal reflux disease, and for the eradication of Helicobacter pylori. However, the therapeutic efficacy of conventional PPIs is considered limited because: (1) they are unstable under acidic conditions and require an enteric-coated formulation in clinical use; (2) they show high interindividual variability in pharmacokinetics due to genetic polymorphisms of cytochrome P450 (CYP) 2C19 metabolism; (3) they have a relatively slow onset of pharmacological...
Source: Advances in Therapy - June 10, 2016 Category: Drugs & Pharmacology Source Type: research

Impact of Pre-existing NS5A-L31 or -Y93H Minor Variants on Response Rates in Patients Infected with HCV Genotype-1b Treated with Daclatasvir/Asunaprevir
Conclusion Optimal SVR rates (≥95%) to DCV/ASV treatment were achieved using DS to exclude patients infected with GT-1b with NS5A RAVs at L31 or Y93H representing ≥20% of their virus population. Exclusion by NGS of patients with minor variants in NS5A (
Source: Advances in Therapy - June 10, 2016 Category: Drugs & Pharmacology Source Type: research

Real-World Effectiveness and Safety of a Live-Attenuated Herpes Zoster Vaccine: A Comprehensive Review
Abstract Abstract Herpes zoster (HZ) is a common, painful and debilitating disease caused by the reactivation of latent varicella-zoster virus in ganglia. This clinical event occurs more frequently in the elderly and those who are immunocompromised. The most common complication of HZ is post-herpetic neuralgia (PHN) which is responsible for the highest HZ-related burden of illness and is challenging to treat. Due to the important clinical and economic impact of HZ and PHN, and the suboptimal treatments that are currently available, HZ vaccination is an important approach to reduce the burden o...
Source: Advances in Therapy - June 4, 2016 Category: Drugs & Pharmacology Source Type: research

Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study
Abstract Introduction In our previous study investigating effects of luseogliflozin, a sodium–glucose cotransporter 2 inhibitor, on 24-h glycemic variability by continuous glucose monitoring (CGM), luseogliflozin elicited parallel downward shifts in fasting and postprandial glucose levels. However, further review of individual patients’ data revealed that postprandial hyperglycemia was not reduced in some patients, while preprandial glucose was ameliorated in most patients. Therefore, we divided patients into two groups according to their postprandial glucose responses and conducte...
Source: Advances in Therapy - June 2, 2016 Category: Drugs & Pharmacology Source Type: research

Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis
Abstract Introduction Cutaneous adverse events (AEs) have been observed in clinical studies of daclizumab high-yield process (HYP) in relapsing-remitting multiple sclerosis (RRMS). Here, we report cutaneous AEs observed in the randomized, double-blind, active-comparator DECIDE study (ClinicalTrials.gov identifier, NCT01064401). Methods DECIDE was a randomized, double-blind, active-controlled phase 3 study of daclizumab HYP 150 mg subcutaneous every 4 weeks versus interferon (IFN) beta-1a 30 mcg intramuscular (IM) once weekly in RRMS. Treat...
Source: Advances in Therapy - June 1, 2016 Category: Drugs & Pharmacology Source Type: research

An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer
Abstract Androgen deprivation therapy (ADT) is the mainstay palliative treatment for men with locally advanced and metastatic prostate cancer, and aims to reduce testosterone to levels obtained by surgical castration. Use of gonadotropin-releasing hormone (GnRH) agonists predominates among the ADT options. The GnRH agonist, triptorelin is a first-line hormonal therapy that has demonstrated efficacy and safety in clinical trials of patients with locally advanced non-metastatic or metastatic disease. Sustained-release 1-, 3- and 6-month formulations of triptorelin, administered intramuscularly or subcutaneously, hav...
Source: Advances in Therapy - May 31, 2016 Category: Drugs & Pharmacology Source Type: research

Pharmacotherapy for Obesity and Changes in Eating Behavior: a Patient and Physician’s Perspective
This article, co-authored by a patient with obesity, diabetes, and hypertension, and an obesity medicine specialist, discusses the patient’s experience with the onset of diabetes complicating obesity and with her frustration living with these diagnoses until finding an obesity medicine specialist physician who helped her lose weight and reverse her diabetes. The patient continues to maintain a significant weight loss and is diabetes free for 5.5 years after treatment initiation. The physician discusses the application of combination treatment that can be effective in diabetes reversal in such cases. He also disc...
Source: Advances in Therapy - May 31, 2016 Category: Drugs & Pharmacology Source Type: research

Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives
Abstract Trabectedin (ET743, Yondelis®, manufactured by Baxter Oncology GmbH, Halle/Westfalen, Germany, for Janssen Products, LP, Horsham, PA), derived from the marine ascidian, Ecteinascidia turbinata, is a natural alkaloid with multiple complex mechanisms of action. On 23 October 2015, 15 years after the results of the first Phase 1 clinical trial using trabectedin for chemotherapy-resistant solid malignancies was reported, and 8 years after its approval in Europe, the United States Food and Drug Administration (USFDA) finally approved trabectedin for the treatment of unresectable or metastatic lip...
Source: Advances in Therapy - May 27, 2016 Category: Drugs & Pharmacology Source Type: research

Comorbidity Burden in Trial-Aligned Patients with Established Gout in Germany, UK, US, and France: a Retrospective Analysis
Conclusions Patients with established gout such as those included in gout trials have a high burden of established morbidity and new diagnoses of morbid events. Consideration of comorbidities, which greatly exacerbate disease burden, is important in gout management. Funding AstraZeneca. (Source: Advances in Therapy)
Source: Advances in Therapy - May 26, 2016 Category: Drugs & Pharmacology Source Type: research

Effect of Cardiac-Cycle-Synchronized Selective Vagal Stimulation on Heart Rate and Blood Pressure in Rats
Conclusion cssVNS can chronically reduce BP in rats avoiding measurable bradycardic side effects. This energy-efficient technique might allow the implementation of sVNS using an implantable device to permanently lower BP in patients. Funding The study was funded by Bundesministerium fur Bildung und Forschung/German Federal Ministry of Education and Research among the call “Individualisierte Medizintechnik” under the grant number FKZ 13GW0120B. (Source: Advances in Therapy)
Source: Advances in Therapy - May 24, 2016 Category: Drugs & Pharmacology Source Type: research

Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2− Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy
The objective of this study was to analyze medical costs and healthcare resource utilization (HRU) associated with everolimus-based therapy or chemotherapy among elderly women with hormone-receptor-positive, human-epidermal-growth-factor-receptor-2-negative (HR+/HER2−) metastatic breast cancer (mBC). Methods Elderly women (≥65 years) with HR+/HER2− mBC who failed a non-steroidal-aromatase-inhibitor and subsequently began a new line of treatment with everolimus-based therapy or chemotherapy for mBC (index therapy) during July 20, 2012 to March 31, 2014 were identif...
Source: Advances in Therapy - May 23, 2016 Category: Drugs & Pharmacology Source Type: research

Breaking Barriers to Effective Type 2 Diabetes Management: Findings from the use of the OPTIMA© Questionnaire in Clinical Practice
Conclusion The OPTIMA questionnaire facilitates communication between patients and their physicians and promotes the set-up of micro-objectives concerning T2DM management. The Physical activity module was the most likely of the five modules in the questionnaire to lead to the set-up of SMART micro-objectives. Funding MSD France. (Source: Advances in Therapy)
Source: Advances in Therapy - May 18, 2016 Category: Drugs & Pharmacology Source Type: research

Development and Evaluation of a New Technological Way of Engaging Patients and Enhancing Understanding of Drug Tolerability in Early Clinical Development: PROACT
Conclusion Overall, PROACT achieved proof of concept in this small pilot study and delivered a secure end-to-end system that protected patient privacy and provided preliminary insight into patient experiences beyond the usual clinical trial data set. The use of mobile devices to interact actively with participants in clinical trials may be a new way of engaging and empowering patients. Further validation of this technology in larger patient cohorts is ongoing. Funding AstraZeneca. (Source: Advances in Therapy)
Source: Advances in Therapy - May 11, 2016 Category: Drugs & Pharmacology Source Type: research

Erratum to: Quality of Life in Glaucoma: A Review of the Literature
(Source: Advances in Therapy)
Source: Advances in Therapy - May 11, 2016 Category: Drugs & Pharmacology Source Type: research

Renal Function in Nucleos(t)ide Analog-Treated Patients With Chronic Hepatitis B: A Systematic Literature Review and Network Meta-Analysis
Conclusion The systematic literature review and network meta-analysis provide evidence that telbivudine is associated with significant improvement in renal function in patients with CHB, either alone or in combination with other NAs. Funding Novartis Pharma AG. (Source: Advances in Therapy)
Source: Advances in Therapy - May 4, 2016 Category: Drugs & Pharmacology Source Type: research

Cost-Effectiveness of Different Forms of Intra-Articular Injections for the Treatment of Osteoarthritis of the Knee
Conclusion The present study showed several HA products to be cost-effective in comparison to conventional care, with Euflexxa having the most favorable cost/QALY gained ratio compared to the other HA products. Funding Ferring Pharmaceutics Inc. (Source: Advances in Therapy)
Source: Advances in Therapy - May 4, 2016 Category: Drugs & Pharmacology Source Type: research

Clinical and Biological Principles of Cold Atmospheric Plasma Application in Skin Cancer
Abstract Plasma-based electrosurgical devices have long been employed for tissue coagulation, cutting, desiccation, and cauterizing. Despite their clinical benefits, these technologies involve tissue heating and their effects are primarily heat-mediated. Recently, there have been significant developments in cold atmospheric pressure plasma (CAP) science and engineering. New sources of CAP with well-controlled temperatures below 40 °C have been designed, permitting safe plasma application on animal and human bodies. In the last decade, a new innovative field, often referred to as plasma medicine, which com...
Source: Advances in Therapy - May 3, 2016 Category: Drugs & Pharmacology Source Type: research

Weight Loss: A Patient and Physician’s Perspective
This article, co-authored by a patient affected by obesity and an obesity medicine specialist, discusses the patient’s experience of living with the disease and using many different weight loss approaches until finding a lifestyle program that was appropriate for her metabolism. The physician discusses the scientific basis of insulin resistance, and why the chosen lifestyle program worked so well for this individual. (Source: Advances in Therapy)
Source: Advances in Therapy - May 3, 2016 Category: Drugs & Pharmacology Source Type: research

Retrospective Evaluation of a Fixed-Dose Combination of Oxycodone and Acetaminophen to Manage Moderate Pain: The Lower the Better
Conclusion A low-dose combination of oxycodone with acetaminophen can be effective in the management of moderate pain and may help in reducing the treatment-associated adverse reactions and drug dependence. Funding Sponsorship for article processing charges was provided by Molteni Farmaceutici, Florence, Italy. (Source: Advances in Therapy)
Source: Advances in Therapy - May 3, 2016 Category: Drugs & Pharmacology Source Type: research

Mechanism-Oriented Therapy of Irritable Bowel Syndrome
Abstract Irritable bowel syndrome (IBS) is a common and well-accepted diagnosis but often imprecisely applied to patients in usual clinical practice. Diagnosis is entirely based on symptom criteria that tend to include broad strata of abdominal complainers. Established criteria for diagnosis are strictly followed in controlled clinical trials for new therapeutic agents, but physicians are more lax in the clinic. Predictably, in light of the above ambiguities, many pathogenetic mechanisms and pathophysiological disturbances appear to be involved in IBS, but so far no mechanism-based subgroupings to guide specific t...
Source: Advances in Therapy - April 30, 2016 Category: Drugs & Pharmacology Source Type: research

Quality of Life in Glaucoma: A Review of the Literature
Abstract The ultimate goal of glaucoma management is the preservation of patients’ visual function and quality of life (QoL). The disease itself as well as the medical or surgical treatment can have an enormous impact on a patient’s QoL. Even the mere diagnosis of a chronic, irreversible, potentially blinding disorder can adversely affect the patient’s sense of well-being and QoL by eliciting significant anxiety. Patients with primary open-angle glaucoma rarely present with visual symptoms, at least early in the course of the disease. A better understanding of patient-reported QoL can improve pat...
Source: Advances in Therapy - April 30, 2016 Category: Drugs & Pharmacology Source Type: research

Boston Keratoprosthesis Outcomes in Severe Ocular Chemical Burns in Southern China: A Retrospective Study
Conclusion KPro surgery can restore useful vision in patients suffering from severe chemical burns. However, postoperative VA declined with the development of complications, and ocular surface disorders caused by the chemical burns were associated with a greater incidence of KPro retention failure. The retention rate was comparable in patients using ipsilateral autologous corneal tissue with allograft corneal tissue. Funding Science and Technology Foundation of Guangdong Province of China, Grant Number 2014A020212714. (Source: Advances in Therapy)
Source: Advances in Therapy - April 28, 2016 Category: Drugs & Pharmacology Source Type: research

Guidelines for the Management of Wet Age-Related Macular Degeneration: Recommendations from a Panel of Greek Experts
Conclusion The introduction of anti-VEGF agents revolutionized the treatment of wAMD. Given the complexity of the disease, the emerging new agents and the difference of cases recruited in clinical trials compared to those appearing in every-day practice, it is essential to individualize treatment options taking into account the results of clinical trials. (Source: Advances in Therapy)
Source: Advances in Therapy - April 26, 2016 Category: Drugs & Pharmacology Source Type: research

Local Injection of Bone Mesenchymal Stem Cells and Fibrin Glue Promotes the Repair of Bone Atrophic Nonunion In Vivo
Conclusion The repair of bone atrophic nonunion can be promoted through local injection of BMSCs and fibrin glue. (Source: Advances in Therapy)
Source: Advances in Therapy - April 20, 2016 Category: Drugs & Pharmacology Source Type: research

Adherence to Long-Term Interferon Beta-1b Injection Therapy in Patients with Multiple Sclerosis Using an Electronic Diary
Conclusion Persistence in this study was in the published range of observational MS studies. Furthermore, in male patients continuation of therapy might be positively influenced by use of a PDA, and both female and male patients might benefit from an integrated reminder function. In conclusion, electronic diaries reminding patients of upcoming injections can promote an improved adherence to MS therapy. Trial registration ClinicalTrials.gov identifier: NCT00902135. Funding Bayer Vital GmbH. (Source: Advances in Therapy)
Source: Advances in Therapy - April 18, 2016 Category: Drugs & Pharmacology Source Type: research

nab -Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial
Abstract Introduction The phase III MPACT trial in patients with metastatic pancreatic cancer (MPC) demonstrated superior efficacy of nab-paclitaxel (nab-P) plus gemcitabine (Gem) compared with Gem monotherapy, including the primary endpoint of overall survival (OS; median 8.7 vs. 6.6 months; hazard ratio [HR] 0.72; P 
Source: Advances in Therapy - April 16, 2016 Category: Drugs & Pharmacology Source Type: research

Impact of Disease Duration on the Effects of Pramlintide in Type 1 Diabetes: A Post Hoc Analysis of Three Clinical Trials
Abstract Introduction Adjunctive mealtime use of the amylin analog pramlintide improves postprandial hyperglycemia in patients with type 1 diabetes. This post hoc analysis of three randomized trials evaluated whether disease duration affected responses to pramlintide. Methods Patients received mealtime pramlintide 30 or 60 µg (n = 714) or placebo (n = 537) as an adjunct to insulin and were stratified into tertiles by diabetes duration at baseline. Efficacy and safety end points were assessed at week 26 using analysis of cov...
Source: Advances in Therapy - April 12, 2016 Category: Drugs & Pharmacology Source Type: research

Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma
Conclusion TARE assumes an integral role in the management of unresectable HCC and has been validated by numerous studies. (Source: Advances in Therapy)
Source: Advances in Therapy - April 2, 2016 Category: Drugs & Pharmacology Source Type: research

Erratum to: 24-h Efficacy of Glaucoma Treatment Options
(Source: Advances in Therapy)
Source: Advances in Therapy - March 28, 2016 Category: Drugs & Pharmacology Source Type: research

Tiotropium Respimat ® Versus HandiHaler ® : Comparison of Bronchodilator Efficacy of Various Doses in Clinical Trials
Conclusion These findings support the use of the marketed once-daily dose of Respimat 5 μg for the maintenance treatment of patients with COPD. Funding Boehringer Ingelheim. (Source: Advances in Therapy)
Source: Advances in Therapy - March 28, 2016 Category: Drugs & Pharmacology Source Type: research

Laparoscopic Sleeve Gastrectomy Improves Excessive Daytime Sleepiness and Sleep Quality 6 Months Following Surgery: A Prospective Cohort Study
Abstract Introduction Obstructive sleep apnea (OSA) is one of the most important co-morbid conditions related with morbid obesity. Bariatric procedures are associated with significant improvement in OSA. The aim of the current study was to evaluate the effect of bariatric surgery on daytime sleepiness and quality of sleep in patients that had undergone laparoscopic sleeve gastrectomy. Methods Fifty-nine patients were prospectively enrolled in the study. Pre-operative and post-operative (6 months) demographics, medical history, weight, and height of ...
Source: Advances in Therapy - March 26, 2016 Category: Drugs & Pharmacology Source Type: research

FP/FORM Versus FP/SAL Within Clinical Practice: An Updated Budget Impact Analysis in Asthma
Conclusion The use of FP/FORM as an alternative to FP/SAL can result in cost savings for the NHS when assessing drug, administration, monitoring and adverse events costs. The inclusion of data released since the launch of FP/FORM within the budget impact analysis demonstrates that the potential cost savings to the NHS that were previously published are being translated to clinical practice. Funding Mundipharma, UK. (Source: Advances in Therapy)
Source: Advances in Therapy - March 26, 2016 Category: Drugs & Pharmacology Source Type: research

Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis
The objective of this study was to examine healthcare resource utilization (HRU) and costs associated with switching to another tumor necrosis factor alpha inhibitor (TNFi) therapy versus a non-TNFi therapy among patients with rheumatoid arthritis (RA) discontinuing use of an initial TNFi biologic therapy. Methods Patients with ≥2 RA diagnoses who used ≥1 TNFi on or after their initial RA diagnosis were identified in a US employer-based insurance claims database. Patients were selected based on ≥1 claim of another TNFi or a non-TNFi biologic therapy (occurring after 2010, an...
Source: Advances in Therapy - March 24, 2016 Category: Drugs & Pharmacology Source Type: research

Erratum to: Healthcare Cost of Over-Diagnosis of Low-Grade Dysplasia in Barrett’s Esophagus
(Source: Advances in Therapy)
Source: Advances in Therapy - March 22, 2016 Category: Drugs & Pharmacology Source Type: research